Adiposopathy and thyroid disease: tracing the pathway to cardiovascular risk.
Adiposopathy, defined as functionally disturbed adipose tissue mainly composed of large adipocytes and induced by chronic excess of food intake, has been associated with immune, metabolic and endocrine derangements promoting inflammation and, eventually, cardiovascular disease. Adiposopathy may positively influence thyrotropin-stimulating hormone, by raising leptin levels, and triggering autoimmunity. In this regard, it is hypothesized that the increased thyrotropin-stimulating hormone is independent of the negative regulation of the thyroid hormone, thereby constituting a secondary phenomenon and not a causal effect. Replacement therapy with thyroid hormones should therefore be applied following strict individualized consideration. Leptin is involved in the immune response and neuroendocrine appetite regulation, while leptin resistance may further promote autoimmune disease. The lipid derangement in adiposopathy may be aggravated in the presence of hypothyroidism and thus considerably augment cardiovascular risk. Lifestyle-modification counselling, including low-fat dietary intake and regular physical exercise, is today the cornerstone of adiposopathy treatment. Meanwhile, new drug formulations, such as leptin and leptin analogs, 5-HT2C-receptor agonist, and potent thyromimetics, currently comprise a promising armamentarium against adiposity and adiposopathy.
Endocrine Unit, Evgenidion Hospital, University of Athens Medical School, Athens, Greece. ledunt@otenet.gr
Leonidas
L
Duntas
Dragan
D
Micic
D017667:Adipocytes / Q000378:metabolism; D000273:Adipose Tissue / Q000473:pathology*; D050154:Adiposity; D000818:Animals; D002318:Cardiovascular Diseases / Q000209:etiology* / Q000503:physiopathology / Q000517:prevention & control; D002149:Energy Intake; D015444:Exercise; D006801:Humans; D008019:Life Style; D008055:Lipids / Q000097:blood; D012307:Risk Factors; D013959:Thyroid Diseases / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D013963:Thyroid Hormones / Q000627:therapeutic use; D013972:Thyrotropin / Q000378:metabolism
D008055:Lipids; D013963:Thyroid Hormones; D013972:Thyrotropin